SUDARSHAN PHARMA INDUSTRIES LTD
Head Office : 301, Aura Biplex, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com • **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111 / 43331111 / 42221116 (100 line) • **CIN :** L51496MH2008PLC184997

SPIL/CS/SE/2026-2027/42

Date: 12th August 2026

To,
The Listing Department
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

BSE Scrip Code: 543828
BSE Trading Symbol: SUDARSHAN
ISIN: INE00TV01023

Ref: **Regulation 33 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015**
Sub: **Outcome of the Meeting of Board of Directors of the Company held on Wednesday, 12th August, 2026**

Dear Sir / Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, we are submitting herewith Unaudited Standalone & Consolidated Financial Results for the quarter ended on 30th June, 2026 as approved by the Board of Directors of the Company along-with Auditors' Limited Review Report at its meeting held today.

The meeting of the Board of Directors commenced at 5.40 pm and concluded at 8.00 pm.

We request you to kindly take the above information on record.

Thanks & Regards,
Yours faithfully,

For Sudarshan Pharma Industries Limited

N. Shah

Nirav Shah
Company Secretary & Compliance Officer

SUDARSHAN PHARMA INDUSTRIES LTD. MUMBAI

SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com
Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Unaudited Standalone Financial Results for Quarter Ended June 30, 2026

(Figures are ₹ in Lakhs) (unless specified otherwise '0 'denotes amounts less than ₹ Five Hundred)

Sr. No.	Particulars	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Unaudited) Refer note 4	(Unaudited)	(Audited)
	Income:				
	Revenue from operations	16,566.03	19,980.98	14,231.10	66,749.85
	Other income	135.38	320.79	141.46	840.44
A	**Total income**	**16,701.41**	**20,301.77**	**14,372.56**	**67,590.29**
	Expenses:				
	Cost of material consumed	107.25	105.65	67.94	297.68
	Purchase of stock-in-trade	15,879.80	19,356.54	13,888.58	65,599.01
	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(1,868.15)	(2,328.75)	(1,212.47)	(7,063.44)
	Employee benefit expense	172.89	184.80	126.25	618.97
	Finance cost	819.46	727.39	571.30	2,529.74
	Depreciation and amortisation expense	129.12	100.36	78.98	340.65
	Other expenses	647.29	832.40	332.60	2,400.87
B	**Total expenses**	**15,887.66**	**18,978.40**	**13,853.18**	**64,723.48**
C	**Profit/(Loss) before exceptional items and tax for the period (A-B)**	**813.75**	**1,323.37**	**519.38**	**2,866.82**
	Exceptional Items	-	-	-	-
D	**Profit before tax**	**813.75**	**1,323.37**	**519.38**	**2,866.82**
E	**Tax expense**				
(a)	Current tax	217.95	315.26	117.00	683.92
(b)	Deferred tax	(8.38)	53.83	29.10	(15.27)
F	**Total tax expense (D-E)**	**209.57**	**369.09**	**146.10**	**668.65**
G	**Net profit for the period/ year (D-F))**	**604.18**	**954.28**	**373.28**	**2,198.16**
H	**Other comprehensive income, net of income tax**				
	i) items that will not be reclassified to profit or loss	0.51	5.53	(1.16)	2.04
	ii) income tax relating to items that will not be reclassified to profit or loss	(0.13)	(1.39)	0.29	(0.51)
	Total other comprehensive income, net of income tax	**0.38**	**4.14**	**(0.87)**	**1.53**
I	**Total comprehensive income for the period/ year**	**604.56**	**958.42**	**372.41**	**2,199.69**
	Paid-up equity share capital : (Face value INR 1 each)	2,496.59	2,406.59	2,406.59	2,406.59
J	Other equity				12,863.92
K	**Earnings per share (in Rs.) From Continuing operations:**				
	Basic EPS : (in INR)	0.25	0.40	0.15	0.91
	Diluted EPS : (in INR) (Refer note 11)	0.25	0.39	0.15	0.90

For Sudarshan Pharma Industries Limited

SUDARSHAN PHARMA INDUSTRIES LIMITED MUMBAI

NGST & ASSOCIATES MUMBAI Chartered Accountants

Sachin Mehta (Joint Managing Director)
DIN : 02211178
Place : Mumbai
Date : 12-08-2026

Notes to Standalone Financial Result:

1. The Financial Statement has been reviewed and recommended by Members of the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026. The statutory auditors have issued an unmodified report on these results. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and rules amended from time to time.

2. The Company is engaged in manufacturing of API, Jobwork manufacturing in Pharmaceuticals items and traders in chemicals and solvents in India. The Company is engaged in the business of speciality chemicals only and therefore, there is only one reportable segment. There is no reportable segment and the segment wise disclosure requirement of IND AS 108 on operating segment is not applicable to it.

3. The previous periods' figures have been re-grouped / re-arranged / re-casted wherever necessary to make it comparable with the current period.

4. The figures for the quarter ended March 31, 2026 is the balancing figures between the unaudited figures in respect of the quarters were subjected to limited review by the Statutory Auditors. The management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs. The Auditor's Limited Review Report of the statutory auditors is being filed with BSE Limited and is also available on the Company's website www.sudarshanpharma.com.

5. The Statutory Auditors have conducted a limited review of the above mentioned quarterly results as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Report of the statutory auditors will be uploaded on the BSE portal along with the results and is also available on the Company's website www.sudarshanpharma.com.

6. During the quarter ended 30th June 2026, the Company decided to discontinue its manufacturing operations at the Palghar unit. The decision was taken after evaluating the unit's operating performance and its contribution to the Company's financial results. The closure is expected to help the Company rationalize fixed and operating costs, minimize further losses, and enable management to focus its resources on more sustainable and profitable operations.

7. Vide letter dated 31st July, 2024 to BSE Limited on the progress of the litigation against Regans International DMCC, the Company had won an award in its favour announced by the Dubai Court in lawsuit against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates. According to the award announced, (i) Regans International DMCC and (i) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of UAE Dirham 40,30,934.00 (equivalent to approx. Rs.9,18,82,890/- i.e. Rupees Nine Crores Eighteen Lakhs Eighty-Two Thousand Eight Hundred And Ninety only) along with interest at 5% annually on the adjudged amount until the full payment is made. Till 30th June, 2026, the Company had received an amount of Rs.4,68,00,535/- (including interest) out of the total outstanding amount and the balance would be received by the Company in future.

NGST & ASSOCIATES MUMBAI Chartered Accountants

8. The Board of Directors of the Company accorded its consent to raise funds up to Rs. 1,500 Crores (Rupees Fifteen Hundred Crores) by issuing Foreign Currency Convertible Bonds (FCCBs) and other securities. At the Board Meeting held on 15th May 2026, the Directors accorded its approval to issue of upto U.S. $ 20,000,000 8.00% senior unsecured foreign currency convertible bonds due 2029, in one or more tranches. At the Board Meeting held on 21st May 2026, the Directors accorded its approval to issue and allot U.S.$10,000,000 aggregate value of FCCBs to the subscribers, with an option with the Company to procure subscribers for up to an additional U.S.$10,000,000 of Bonds on the same terms within 60 days from the Issue Date and approved and confirmed the allotment of 10,000 8% senior unsecured foreign currency convertible bonds due 2029 of face value of USD 1,000 each, convertible into fully paid-up equity shares of face value of Re.1 each of the Company at a price of Rs.30.19/-.The proceeds of the aforesaid allotment were received in tranches on 27th May 2026 and 4th June 2026 comprising of USD 900,000 and USD 100,000 respectively. The above FCCBs are accounted in accordance with Ind AS 32 on Financial Instruments: Presentation and Ind AS 109 - Financial Instruments.

9. The Warrants Committee of the Company at its Meeting held on 12th June 2026 accorded it's approval to allot 90,00,000 equity shares of face value of Re.1/- each at an issue price of Rs.16.98 each (including a premium of Rs.15.98 each), consequent upon the conversion of 9,00,000 Warrants issued at an Issue Price of Rs.169.83 each on 18th December 2024, to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters, on preferential basis, upon receipt of balance amount aggregating to Rs.11,46,20,000/- per warrant (being 75% of the issue price per warrant) from the allottees pursuant to the exercise of their rights of conversion into equity shares. Consequently, the issued and paid-up capital of the Company stands increased to Rs.24,96,58,870/- consisting of 24,96,58,870 equity shares of Re. 1/- each.

10. The Company has incorporated the following subsidiary company during the quarter ended 30th June 2026: (i) W. e. f. 5th June, 2026, "Sudarshan Industries Inc." (hereinafter referred to as "Sudarshan USA") was incorporated as a wholly-owned subsidiary of the Company. The Company has subscribed to 1,00,00,000 shares of USD0.00001 each of Sudarshan USA (approx. Rs.9,600/-) (100.00% of the paid-up share capital). The main object of Sudarshan USA is to carry on the business to buy, sale, manufacture, process, import, export, promote, develop, wholesale and / or retail trade in all kinds and varieties of pharmaceuticals, antibiotics, drugs, medicines, biological, neutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, pharma intermediates, Active Pharmaceutical lngredients, antibiotics, drugs, medicines, biologicals, neutraceuticals chemicals, chemical products, chemical compounds including speciality chemicals and other allied goods.

11. As at June 30, 2026, there are potential dilutive equity share in the nature of FCCB. The potential dilutive equity shares has an anti-dilutive effect. Hence no dilution effect has been considered for the quarter ended June 30, 2026.

For Sudarshan Pharma Industries Limited

Sachin Mehta (Joint Managing Director)
DIN : 02211178
Place : Mumbai
Date : 12-08-2026

SUDARSHAN PHARMA INDUSTRIES LIMITED MUMBAI

NGST & ASSOCIATES MUMBAI Chartered Accountants

Independent Auditor's Review Report on Review of Interim Standalone Financial Results
To The Board of Directors,
Sudarshan Pharma Industries Limited

We have reviewed the accompanying statement of standalone unaudited financial results of **M/s. Sudarshan Pharma Industries Limited** ("the company") for the quarter ended on 30th June 2026 ("the statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors / Committee of Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel & analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Nothing has come to our notice that causes us to believe that the accompanying statement of standalone unaudited financial results prepared in accordance with the applicable Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR NGST & ASSOCIATES
Chartered Accountants
Firm Reg. No 135159W

Place: Mumbai
Date: 12th August 2026

NGST & ASSOCIATES MUMBAI Chartered Accountants

Twinkal P Jain (Partner)
M. No. 156938
UDIN – 26156938SRSSBV6343

SUDARSHAN PHARMA INDUSTRIES LTD

Head Office : 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.

E-mail : compliance@sudarshanpharma.com, **Website :** www.sudarshanpharma.com

Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Statement of Unaudited Consolidated Financial Results for Quarter Ended June 30, 2026

(Figures are ₹ in Lakhs) (unless specified otherwise '0 'denotes amounts less than ₹ Five Hundred)

Sr. No.	Particulars	Quarter ended			Year Ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		Unaudited	Unaudited (Refer note 2)	Unaudited	Audited
	INCOME				
I	Revenue from operations	17,441.84	22,092.13	14,526.16	70,305.65
II	Other Income	121.97	412.50	120.70	871.30
III	**Total Income (I +II)**	**17,563.81**	**22,504.63**	**14,646.86**	**71,176.95**
IV	**EXPENSES**				
(a)	Cost of material consumed	797.53	2,012.09	541.58	3,905.59
(b)	Purchase of stock-in-trade	16,872.95	19,261.09	13,953.25	65,213.19
(c)	Changes in inventories of finished goods, stock-in-trade and work-in-progress	(2,695.67)	(2,268.31)	(1,573.25)	(7,181.01)
(d)	Employee benefit expense	206.84	210.13	158.41	743.71
(e)	Finance cost	820.71	752.64	595.76	2,570.07
(f)	Depreciation and amortisation expense	140.61	109.27	88.35	378.83
(g)	Other expenses	670.31	857.28	341.85	2,492.61
	Total Expenses (IV (a to g))	**16,813.28**	**20,934.20**	**14,105.95**	**68,122.98**
V	**Profit before tax**	**750.53**	**1,570.43**	**540.91**	**3,053.97**
VI	**Tax expense:**				
	1) Current tax	219.81	343.48	125.67	732.37
	2) Deferred tax	(30.22)	87.72	19.39	(15.57)
	Total Tax Expenses for the period/year	**189.59**	**431.20**	**145.06**	**716.80**
VII	**Net Profit/(Loss) for the period/year from continuing operations**	**560.94**	**1,139.24**	**395.85**	**2,337.17**
	Share of Non-controliing Interest	(24.58)	66.62	(7.82)	6.84
VIII	**Profit for the period/year from operations**	**585.52**	**1,072.62**	**403.67**	**2,330.33**
IX	**Other comprehensive income, net of income tax**				
	A) i) Items that will not be reclassified to profit or loss	0.57	5.86	(1.19)	2.29
	ii) Income tax relating to items that will not be reclassified to profit or loss	(0.14)	(1.48)	0.30	(0.58)
	B) i) Items that will be reclassified to profit or loss	(0.00)	2.98	-	3.33
	ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
	Total other comprehensive income, net of income tax	**0.43**	**7.37**	**(0.89)**	**5.05**
X	**Total comprehensive income for the period/ year (IX+XI))**	**561.37**	**1,146.60**	**394.96**	**2,342.22**
XI	Paid-up equity share capital : (Face value INR 1 each)	2,496.59	2,406.59	2,406.59	2,406.59
XII	Other equity				13,103.03
XIII	Profit and Losses Attributable to:				
	-Owners of the Company	585.52	1,072.62	403.67	2,330.33
	-Non Controlling Interest	(24.58)	66.62	(7.82)	6.84
XVI	Other Comprehensive Income Attributable to:				
	-Owners of the Company	0.43	7.37	(0.89)	5.05
	-Non Controlling Interest	-	-	-	-
XVII	Total Comprehensive Income Attributable to:				
	-Owners of the Company	585.95	1,079.99	402.78	2,335.38
	-Non Controlling Interest	(24.58)	66.62	(7.82)	6.84
XVIII	**Earnings per equity share**				
(i)	Basic: (in Rs.)	0.23	0.48	0.16	0.97
(ii)	Diluted: (in Rs.) (Refer no. 11)	0.23	0.47	0.16	0.97

NGST & ASSOCIATES MUMBAI Chartered Accountants

For Sudarshan Pharma Industries Limited

SUDARSHAN PHARMA INDUSTRIES LIMITED MUMBAI

NGST & ASSOCIATES MUMBAI Chartered Accountants

Sachin Mehta (Joint Managing Director)
DIN : 02211178
Place : Mumbai
Date : 12-08-2026

SUDARSHAN PHARMA INDUSTRIES LTD
Head Office : 301, Aura Biplex, Premium Retail, Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092.
E-mail : compliance@sudarshanpharma.com, **Website** : www.sudarshanpharma.com
Board Line : +91-22-42221111/42221116 (100 line) CIN : L51496MH2008PLC184997

Notes to Consolidated Financial Result:

1. The Statement has been reviewed by Members of the Audit Committee and approved by the Board of Directors at their respective meetings held on August 12, 2026. The statutory auditors have issued an unmodified report on these results. This Statement has been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, 2013 and rules amended from time to time.

2. The Holding Company is engaged in manufacturing of API, Jobwork manufacturing in Pharmaceuticals items and traders in chemicals and solvents in India. The Company is engaged in the business of speciality chemicals only and therefore, there is only one reportable segment. There is no reportable segment and the segment wise disclosure requirement of IND AS 108 on operating segment is not applicable to it.

3. The previous periods' figures have been re-grouped / re-arranged / re-casted wherever necessary to make it comparable with the current period.

4. The figures for the quarter ended March 31, 2026 is the balancing figures between the unaudited figures in respect of the quarters were subjected to limited review by the Statutory Auditors. The management has exercised necessary diligence to ensure that the financial results provide a true and fair view of the Company's affairs. The Auditor's Limited Review Report of the statutory auditors is being filed with BSE Limited and is also available on the Company's website www.sudarshanpharma.com.

5. The Statutory Auditors have conducted a limited review of the above mentioned quarterly and year to date results as required by Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Report of the statutory auditors will be uploaded on the BSE portal along with the results and is also available on the Company's website www.sudarshanpharma.com.

6. During the quarter ended 30th June 2026, the Company decided to discontinue its manufacturing operations at the Palghar unit. The decision was taken after evaluating the unit's operating performance and its contribution to the Company's financial results. The closure is expected to help the Company rationalize fixed and operating costs, minimize further losses, and enable management to focus its resources on more sustainable and profitable operations.

7. Vide letter dated 31st July, 2024 to BSE Limited on the progress of the litigation against Regans International DMCC, the Company had won an award in its favour announced by the Dubai Court in lawsuit against (i) Regans International DMCC and (ii) Nand Biharilal Chhabaria Biharilal Chunilal in Dubai, United Arab Emirates. According to the award announced, (i) Regans International DMCC and (i) Nand Biharilal Chhabaria Biharilal Chunilal have been ordered to pay to the Company an amount of UAE Dirham 40,30,934.00 (equivalent to approx. Rs.9,18,82,890/- i.e. Rupees Nine Crores Eighteen Lakhs Eighty Two Thousand Eight Hundred And Ninety only) along with interest at 5% annually on the adjudged amount until the full payment is made. Till 30th June, 2026, the Company had received an amount of Rs.4,68,00,535/- (including interest) out of the total outstanding amount and the balance would be received by the Company in future.

NGST & ASSOCIATES MUMBAI

8. The Board of Directors of the Company accorded it's consent to raise funds up to Rs.1,500 Crores (Rupees Fifteen Hundred Crores) by issuing Foreign Currency Convertible Bonds (FCCBs) and other securities. At the Board Meeting held on 15th May 2026, the Directors accorded its approval to issue of upto U.S. $ 20,000,000 8.00% senior unsecured foreign currency convertible bonds due 2029, in one or more tranches. At the Board Meeting held on 21st May 2026, the Directors accorded its approval to issue and allot U.S.$10,000,000 aggregate value of FCCBs to the subscribers, with an option with the Company to procure subscribers for up to an additional U.S.$10,000,000 of Bonds on the same terms within 60 days from the Issue Date and approved and confirmed the allotment of 10,000 8% senior unsecured foreign currency convertible bonds due 2029 of face value of USD 1,000 each, convertible into fully paid-up equity shares of face value of Re.1 each of the Company at a price of Rs.30.19/-.The proceeds of the aforesaid allotment were received in tranches on 27th May 2026 and 4th June 2026 comprising of USD 900,000 and USD 100,000 respectively. The above FCCBs are accounted in accordance with Ind AS 32 on Financial Instruments: Presentation and Ind AS 109 - Financial Instruments.

9 The Warrants Committee of the Company at its Meeting held on 12th June 2026 accorded it's approval to allot 90,00,000 equity shares of face value of Re.1/- each at an issue price of Rs.16.98 each (including a premium of Rs.15.98 each), consequent upon the conversion of 9,00,000 Warrants issued at an Issue Price of Rs.169.83 each on 18th December 2024, to Mr. Hemal Mehta and Mr. Sachin Mehta, Promoters, on preferential basis, upon receipt of balance amount aggregating to Rs.11,46,20,000/- per warrant (being 75% of the issue price per warrant) from the allottees pursuant to the exercise of their rights of conversion into equity shares. Consequently, the issued and paid-up capital of the Company stands increased to Rs.24,96,58,870/- consisting of 24,96,58,870 equity shares of Re. 1/- each.

10 The Company has incorporated the following subsidiary company during the quarter ended 30th June 2026: W. e. f. 5th June, 2026, "Sudarshan Industries Inc." (hereinafter referred to as "**Sudarshan USA**") was incorporated as a wholly-owned subsidiary of the Company. The Company has subscribed to 1,00,00,000 shares of USD0.00001 each of Sudarshan USA (approx. Rs.9,600/-) (100.00% of the paid-up share capital). The main object of Sudarshan USA is to carry on the business to buy, sale, manufacture, process, import, export, promote, develop, wholesale and / or retail trade in all kinds and varieties of pharmaceuticals, antibiotics, drugs, medicines, biological, neutraceuticals, healthcare, ayurvedic and dietary supplement products, medicinal preparations, vaccines, pharma intermediates, Active Pharmaceutical lngredients, antibiotics, drugs, medicines, biologicals, neutraceuticals chemicals, chemical products, chemical compounds including speciality chemicals and other allied goods.

11 As at June 30, 2026, there are potential dilutive equity share in the nature of FCCB. The potential dilutive equity shares has an anti-dilutive effect. Hence no dilution effect has been considered for the quarter ended June 30, 2026.

NGST & ASSOCIATES MUMBAI Chartered Accountants

12 The accounts of the following subsidiaries of the Holding company have been considered while preparing consolidated Financial Results / Statements of the Group:

* Sudarshan Pharma Lifescience Private Limited
* Lifescience Chemical Private Limited
* Ratna Lifesciences Private Limited
* Sudarshan Maven Pharma Private Limited
* Ishwari Healthcare Private Limited
* Sudarshan Pharma Industries Private Limited, Singapore
* Cibachem General Trading LLC, Dubai (w.e.f 5th August 2025)
* Sudarshan Pharma Poland Limited Liability Company, Poland (w.e.f. 17th December 2025)
* Sudarshan Industries Inc, USA (w.e.f. 5th June 2026)

For Sudarshan Pharma Industries Limited

SUDARSHAN PHARMA INDUSTRIES LIMITED MUMBAI

Sachin Mehta (Joint Managing Director)
DIN : 02211178
Place : Mumbai
Date : 12-08-2026

NGST & ASSOCIATES MUMBAI Chartered Accountants

Independent Auditor's Review Report on Review of Interim Consolidated Financial Results
To The Board of Directors
Sudarshan Pharma Industries Limited

We have reviewed the accompanying statement of consolidated unaudited financial results of **M/s. Sudarshan Pharma Industries Limited** ("The Company") for the quarter ended on 30th June 2026 ("The Statement"), being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.

This statement is the responsibility of the Company's Management and has been approved by the Board of Directors/Committee of Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India.

Our responsibility is to issue a report on these financial statements based on our review. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel & analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The Statement includes the results of following entities in so far as they relate to the Consolidated Financial Results:
Subsidiary Companies –

1. Sudarshan Pharma Lifescience Private Limited
2. Lifescience Chemical Private Limited
3. Ratna Lifesciences Private Limited
4. Sudarshan Maven Pharma Private Limited
5. Sudarshan Pharma Industries Private Limited, Singapore
6. Ishwari Healthcare Private Limited
7. Cibachem General Trading LLC, Dubai
8. Sudarshan Pharma Poland Limited Liability Company, Poland
9. Sudarshan Industries Inc, USA

We did not review the financial results of five subsidiaries, namely, Sudarshan Pharma Industries Private Limited, Singapore; Ishwari Healthcare Private Limited; Cibachem General Trading LLC, Dubai; Sudarshan Pharma Poland Limited Liability Company, Poland; and Sudarshan Industries Inc., USA. The financial results of these subsidiaries have been certified by their respective managements and have not been reviewed by us or by any other auditor. Accordingly, our conclusion, insofar as it relates to the amounts and disclosures pertaining to these subsidiaries, is based solely on the respective management certifications provided to us. Our conclusion is not modified in respect of this matter.

Nothing has come to our notice that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the applicable Indian Accounting Standards as prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other accounting principles generally accepted in India has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI

NGST & ASSOCIATES MUMBAI Chartered Accountants

(Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

FOR NGST & ASSOCIATES
Chartered Accountants
Firm Reg. No 135159W

Place: Mumbai
Date: 12th August 2026

Twinkal P Jain (Partner)
M. No. 156938
UDIN –26156938LRCMVA7072